Lisinopril vs Amlodipine: Head-to-Head Efficacy Compared

How the Two Drugs Lower Blood Pressure

Lisinopril and amlodipine reduce blood pressure through entirely different mechanisms, which is why clinicians frequently combine them. Lisinopril blocks angiotensin-converting enzyme, reducing the production of angiotensin II and lowering peripheral vascular resistance over days to weeks. Amlodipine blocks L-type calcium channels in vascular smooth muscle, causing direct arterial vasodilation within hours of the first dose.

Both drugs are first-line agents for hypertension according to the 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure [1]. The guideline recommends thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers as equally acceptable initial choices for stage 1 hypertension in most adults.

In a meta-analysis of 354,000 patients across 32 trials published in the BMJ, the Blood Pressure Lowering Treatment Trialists' Collaboration found that each 5 mmHg reduction in systolic blood pressure reduced major cardiovascular events by approximately 10%, regardless of which drug class produced that reduction [2]. The practical difference between lisinopril and amlodipine, then, often comes down to their secondary effects on specific organ systems, tolerability profiles, and the patient's comorbid conditions.

Amlodipine reaches peak plasma concentration at 6 to 12 hours, with a half-life of 30 to 50 hours. This long half-life makes it forgiving of missed doses. Lisinopril peaks at about 7 hours with a half-life of 12 hours, though its tissue-level ACE inhibition persists for 24 hours in most patients, allowing once-daily dosing [3].

ALLHAT: The Largest Antihypertensive Trial Ever Run

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) remains the single largest randomized antihypertensive study in history, enrolling 33,357 participants aged 55 and older with hypertension and at least one coronary heart disease risk factor. Participants were randomized to chlorthalidone (a thiazide diuretic), amlodipine, lisinopril, or doxazosin (the doxazosin arm was stopped early) [4].

The primary outcome was combined fatal coronary heart disease or nonfatal myocardial infarction over a mean follow-up of 4.9 years. The results were clear on this point: no statistically significant difference existed between the lisinopril and amlodipine arms for the primary endpoint (RR 0.99, 95% CI 0.91 to 1.08) [4].

Secondary outcomes told a more nuanced story. The lisinopril arm showed a 15% higher rate of stroke compared to chlorthalidone (RR 1.15, 95% CI 1.02 to 1.30). Amlodipine did not carry this excess stroke risk. The lisinopril arm also had a 10% higher rate of combined cardiovascular disease (RR 1.10, 95% CI 1.05 to 1.16) relative to chlorthalidone, driven largely by higher rates of stroke, heart failure, and angina [4].

One important caveat: mean achieved systolic blood pressure was 2 mmHg higher in the lisinopril arm than the chlorthalidone arm at every follow-up visit. Some of the apparent outcome differences may reflect this blood pressure gap rather than an intrinsic inferiority of ACE inhibition.

The ALLHAT heart failure findings were striking. Lisinopril had a lower 6-year heart failure rate than amlodipine (RR 0.81, P<0.001 for the comparison of amlodipine vs chlorthalidone showed higher HF in the amlodipine group), though all arms were compared against chlorthalidone as the reference. In the amlodipine vs chlorthalidone comparison, amlodipine was associated with a 38% higher risk of heart failure (RR 1.38, 95% CI 1.25 to 1.52) [4].

ASCOT-BPLA: Advantage for Amlodipine-Based Regimens

The Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Lowering Arm (ASCOT-BPLA) randomized 19,257 patients with hypertension and at least three cardiovascular risk factors to either amlodipine (with perindopril added as needed) or atenolol (with bendroflumethiazide added as needed) [5].

The trial was stopped early at a median of 5.5 years because of significant differences in secondary endpoints favoring the amlodipine-based arm. The primary endpoint (nonfatal MI and fatal coronary heart disease) did not reach significance (HR 0.90, 95% CI 0.79 to 1.02, P=0.1052). However, the amlodipine-based regimen showed a 23% reduction in fatal and nonfatal stroke (HR 0.77, 95% CI 0.66 to 0.89, P=0.0003), a 16% reduction in total cardiovascular events and procedures (HR 0.84, 95% CI 0.78 to 0.90, P<0.0001), and a 24% reduction in cardiovascular mortality (HR 0.76, 95% CI 0.65 to 0.90, P=0.001) [5].

ASCOT-BPLA compared amlodipine against atenolol, not lisinopril. The results cannot be directly applied to a lisinopril vs amlodipine comparison. Atenolol has fallen out of favor as a first-line antihypertensive, and some of the disadvantage in the atenolol arm likely reflected the inferior metabolic and hemodynamic profile of that specific beta-blocker rather than the superiority of amlodipine over all other classes.

"The ASCOT results reinforced the concept that amlodipine-based therapy provides consistent stroke protection, but the comparator was atenolol, not an ACE inhibitor. Extrapolating to a lisinopril comparison requires caution." This assessment from Dr. Bryan Williams, lead author of the 2018 ESC/ESH Hypertension Guidelines, highlights why indirect comparisons between ALLHAT and ASCOT-BPLA have limits [6].

Stroke Prevention: Where the Data Diverge

Across multiple meta-analyses, calcium channel blockers as a class appear to have a modest advantage over ACE inhibitors for stroke prevention, independent of blood pressure reduction. A Lancet meta-analysis by the Blood Pressure Lowering Treatment Trialists' Collaboration (2003) found that CCBs reduced stroke risk by 7% more than ACE inhibitors (RR 0.93, 95% CI 0.86 to 1.00), though this was borderline significant [7].

The proposed mechanism is that dihydropyridine CCBs like amlodipine produce more consistent 24-hour blood pressure control with less visit-to-visit variability. A study by Rothwell et al. in The Lancet Neurology (2010) demonstrated that higher visit-to-visit systolic blood pressure variability was an independent predictor of stroke, and that CCBs reduced this variability more than other antihypertensive classes [8].

For a patient whose primary concern is stroke prevention, especially one with a prior transient ischemic attack or a strong family history of cerebrovascular disease, amlodipine may be the preferred first-line agent. The advantage is modest in absolute terms. In ALLHAT, the stroke rate difference between the lisinopril and chlorthalidone arms translated to roughly 2 additional strokes per 1,000 patient-years in the lisinopril group.

Kidney Protection: ACE Inhibitors Lead

Where lisinopril clearly outperforms amlodipine is in proteinuric kidney disease. ACE inhibitors reduce intraglomerular pressure by dilating the efferent arteriole, a mechanism calcium channel blockers do not share. The KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease recommends ACE inhibitors or ARBs as first-line therapy in patients with CKD and albuminuria (albumin-to-creatinine ratio ≥30 mg/g) [9].

The REIN trial showed that ramipril (another ACE inhibitor) reduced the rate of GFR decline by 50% compared to placebo in patients with proteinuric nephropathy [10]. While this trial used ramipril and not lisinopril, the effect is considered a class effect of ACE inhibitors. No comparable renal-protective benefit has been demonstrated for amlodipine in proteinuric CKD.

For patients with diabetic nephropathy, the advantage is even more pronounced. The 2022 ADA Standards of Care recommend ACE inhibitors or ARBs for all patients with type 2 diabetes and a urine albumin-to-creatinine ratio ≥30 mg/g, regardless of blood pressure [11]. Amlodipine can be added as a second agent for blood pressure control, but it does not replace the ACE inhibitor's role in nephroprotection.

One exception: in patients with non-proteinuric hypertension (no significant albuminuria), neither class has demonstrated superiority for kidney outcomes. Blood pressure control itself is the primary driver of renal preservation in this population.

Heart Failure Considerations

The ALLHAT data raised concerns about amlodipine and heart failure. The amlodipine arm had a 38% higher rate of heart failure hospitalization compared to chlorthalidone [4]. This finding has been debated extensively. Some investigators argue that amlodipine's vasodilatory effects cause reflex neurohormonal activation and fluid retention, which can unmask or worsen heart failure. Others note that chlorthalidone's diuretic properties may have masked heart failure symptoms in that arm, artificially lowering the event rate.

For patients with established heart failure with reduced ejection fraction (HFrEF), ACE inhibitors are a cornerstone of guideline-directed medical therapy. The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure gives ACE inhibitors a Class I recommendation for HFrEF [12]. Amlodipine is one of the few CCBs considered safe in heart failure (the PRAISE trial showed it did not increase mortality), but it is not a primary treatment [13].

"ACE inhibitors remain fundamental to the neurohormonal blockade strategy in heart failure with reduced ejection fraction. They should not be replaced by calcium channel blockers in this population." This statement from the 2022 AHA heart failure guideline underscores the distinction [12].

If a patient has both hypertension and HFrEF, lisinopril is the clear first choice. If a patient has hypertension with preserved ejection fraction and no proteinuria, either drug is reasonable.

Side Effect Profiles Compared

The tolerability differences between lisinopril and amlodipine are distinct and predictable. Lisinopril causes a dry, persistent cough in 5% to 20% of patients, driven by bradykinin accumulation in the lungs. This cough is more common in women and in patients of East Asian descent. It is the most common reason patients discontinue ACE inhibitors [14].

Amlodipine's signature side effect is dose-dependent peripheral edema, occurring in roughly 1.8% of patients at 5 mg and up to 10.8% at 10 mg [15]. This edema is caused by precapillary arteriolar dilation without matching venous dilation, leading to increased capillary hydrostatic pressure. It is not a sign of fluid overload and does not respond well to diuretics. Reducing the dose or adding an ACE inhibitor (which dilates postcapillary venules) can reduce the edema.

Angioedema is rare with lisinopril (0.1% to 0.7%) but potentially life-threatening. It occurs more frequently in Black patients [14]. Amlodipine does not carry this risk.

Both drugs are pregnancy category D (lisinopril) and category C (amlodipine), but ACE inhibitors are absolutely contraindicated in pregnancy due to fetal renal toxicity. Amlodipine is not preferred in pregnancy either; methyldopa, labetalol, and nifedipine are the standard choices.

Lisinopril can raise serum potassium, particularly in patients with CKD or those on potassium-sparing diuretics. Amlodipine is potassium-neutral. Neither drug causes the metabolic disturbances (glucose elevation, lipid changes) associated with older beta-blockers or thiazide diuretics at high doses.

When Clinicians Choose One Over the Other

Clinical decision-making between lisinopril and amlodipine follows a pattern driven by the patient's comorbidities, demographics, and tolerability.

Lisinopril is generally preferred when the patient has diabetes with albuminuria, chronic kidney disease with proteinuria, heart failure with reduced ejection fraction, or a post-myocardial infarction history. The 2023 ESH Guidelines for the Management of Arterial Hypertension recommend ACE inhibitors as a preferred component of combination therapy in these populations [16].

Amlodipine is often favored in older patients with isolated systolic hypertension, patients with a history of ACE inhibitor cough, Black patients (who tend to have a blunted response to ACE inhibitor monotherapy per ALLHAT subgroup analysis), and patients whose primary risk is stroke [4, 5].

For most patients without these specific indicators, the choice is genuinely flexible. Both drugs appear in every major guideline's first-line recommendations. Cost is comparable. Both are once-daily.

The most common real-world scenario is that patients end up on both. The 2017 ACC/AHA guideline recommends initiating two-drug therapy for patients with stage 2 hypertension (systolic ≥140 or diastolic ≥90 mmHg), and an ACE inhibitor plus a CCB is one of the preferred two-drug combinations [1]. Fixed-dose combination pills containing an ACE inhibitor and amlodipine are available and improve adherence.

Switching Between the Two Drugs

Switching from lisinopril to amlodipine (or vice versa) is straightforward and does not require a washout period. The most common reason for switching from lisinopril to amlodipine is ACE inhibitor cough. The cough typically resolves within 1 to 4 weeks of discontinuation [14].

When switching from amlodipine to lisinopril (usually for renal protection or heart failure management), clinicians may overlap the drugs briefly while titrating the new agent. Amlodipine's long half-life means its blood-pressure-lowering effect persists for 2 to 3 days after the last dose, providing a natural transition window.

Dose equivalence is approximate. Lisinopril 10 mg and amlodipine 5 mg produce roughly similar reductions in systolic blood pressure (8 to 10 mmHg), though individual responses vary considerably [3, 15]. Home blood pressure monitoring during the transition period is recommended.

Patients should not stop either medication abruptly without medical guidance. While neither drug causes rebound hypertension in the way clonidine does, uncontrolled blood pressure during any gap in treatment increases short-term cardiovascular risk, particularly in patients with existing vascular disease.

The Bottom Line on Direct Comparison

No large randomized trial has directly compared lisinopril to amlodipine as a primary endpoint. ALLHAT compared both against chlorthalidone, and ASCOT-BPLA compared amlodipine against atenolol. The indirect evidence suggests equivalent efficacy for preventing myocardial infarction, a modest stroke-prevention advantage for amlodipine, and a clear advantage for lisinopril in proteinuric kidney disease and heart failure with reduced ejection fraction. For patients requiring treatment intensification, combining both drugs is well supported by guidelines and addresses complementary pathways of blood pressure regulation. The 2023 ESH Guidelines specifically identify ACE inhibitor plus CCB as one of the two preferred initial dual combinations for hypertension management [16].